Silverberg Jonathan I, Kantor Robert
Department of Dermatology, Northwestern University Feinberg School of Medicine, 676 North St. Clair Street, Suite 1600, Chicago, IL 60611, USA; Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, 676 North St. Clair Street, Suite 1600, Chicago, IL 60611, USA; Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, 676 North St. Clair Street, Suite 1600, Chicago, IL 60611, USA.
Department of Dermatology, Northwestern University Feinberg School of Medicine, 676 North St. Clair Street, Suite 1600, Chicago, IL 60611, USA.
Dermatol Clin. 2017 Jul;35(3):327-334. doi: 10.1016/j.det.2017.02.005. Epub 2017 Apr 22.
Moderate to severe atopic dermatitis (AD) can be debilitating and often requires use of systemic immunosuppressant therapy to achieve adequate disease control. There are currently no US Food and Drug Administration-approved systemic agents for the long-term treatment of AD. Recent insight has identified the T helper 2 cytokines, interleukins 4 and 13, as playing a major role in the pathogenesis of AD. There are multiple novel biologic agents in development that target interleukins 4 and/or 13 for the treatment of moderate to severe AD. The age of targeted biologics for AD has arrived.
中度至重度特应性皮炎（AD）可能使人虚弱，通常需要使用全身性免疫抑制疗法来实现充分的疾病控制。目前美国食品药品监督管理局尚未批准用于AD长期治疗的全身性药物。最近的研究发现，辅助性T细胞2细胞因子白细胞介素4和13在AD的发病机制中起主要作用。目前有多种新型生物制剂正在研发中，它们靶向白细胞介素4和/或13用于治疗中度至重度AD。针对AD的靶向生物制剂时代已经到来。
